Mustafa Deryal
cts CaritasKlinikum Saarbrücken(DE)Klinikum Saarbrücken(DE)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy
Most-Cited Works
- → Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial(2020)158 cited
- → Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer(2023)66 cited
- → DNMT1 genetic polymorphisms affect breast cancer risk in the central European Caucasian population(2013)34 cited
- → INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line(2023)25 cited
- → Axillary dissection in primary breast cancer: variations of the surgical technique and influence on morbidity(2012)19 cited
- ESR1 single nucleotide polymorphisms predict breast cancer susceptibility in the central European Caucasian population.(2013)
- → Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects(2025)3 cited
- → Abstract PD11-03: PD11-03 Comparison of a mono Atezolizumab window followed by Atezolizumab and chemotherapy with Atezolizumab and chemotherapy in triple negative breast cancer – an interim analysis of the adaptive randomized neoadjuvant trial NeoMono(2023)3 cited
- → Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy +/- a preceding atezolizumab monotherapy window: A translational analysis of the neoMono trial.(2023)3 cited
- → NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.(2020)3 cited